S121: CD123-CD33 COMPOUND CAR-T CELLS WITH NOVEL ANTIGEN BINDING DOMAINS PROVIDE A NEW HOPE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

S121: CD123-CD33 COMPOUND CAR-T CELLS WITH NOVEL ANTIGEN BINDING DOMAINS PROVIDE A NEW HOPE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

Bibliographic Details
Main Authors:	Z. Wang, Y. LU, S. Qiu, M. Wang, D. Xiong, J. Wang
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843376.67667.04

Similar Items

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
by: Justin C. Boucher, et al.
Published: (2023-12-01)

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
by: Zhenzhen Wang, et al.
Published: (2023-10-01)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
by: Michael A. Morgan, et al.
Published: (2021-07-01)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
by: Gaia Alberti, et al.
Published: (2023-05-01)

Molecular cloning of two isoforms of the murine homolog of the myeloid CD33 antigen.
by: Tchilian, E, et al.
Published: (1994)

89723 CD105-targeted CAR T cells for the treatment of acute myeloid leukemia
by: Konstantinos Lontos, et al.
Published: (2021-03-01)

Evaluation of CD96 and CD123 in CD34+ leukemic stem cells in acute myeloid leukemia patients and their relation to response to induction therapy
by: Haidar H Al-Fatlawi, et al.
Published: (2016-01-01)

CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
by: Elvira Pelosi, et al.
Published: (2023-02-01)

Control effect of Dasatinib on the treatment of acute myeloid leukemia and adverse events of CD123 targeting CAR-T: a case report and literature review
by: LI Chunmin, et al.
Published: (2024-02-01)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
by: Ivetta Danylesko, et al.
Published: (2023-08-01)

Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia
by: Gongqiang Wu, et al.
Published: (2023-02-01)

First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia
by: Michael Boyiadzis, et al.
Published: (2023-03-01)

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
by: Danni Xie, et al.
Published: (2023-08-01)

Immunosuppressive role of CD11b+CD33+HLA‐DR− myeloid‐derived suppressor cells‐like blast subpopulation in acute myeloid leukemia
by: Shin Young Hyun, et al.
Published: (2020-10-01)

SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia
by: Hannah Åbacka, et al.
Published: (2024-04-01)

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
by: Matteo Molica, et al.
Published: (2021-06-01)

Anti‐CLL1‐based CAR T‐cells with 4‐1‐BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia
by: Kunlin Pei, et al.
Published: (2023-04-01)

A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia
by: Shilin Xu, et al.
Published: (2021-11-01)

FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
by: Eugenio Galli, et al.
Published: (2024-02-01)

Prognostic value of cross‐lineage expression of the myeloid‐associated antigens CD13 and CD33 in adult B‐lymphoblastic leukemia: A large real‐world study of 1005 patients
by: Hongyan Liao, et al.
Published: (2023-04-01)

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
by: Simona Caruso, et al.
Published: (2022-11-01)

1352 An MHC class II targeted immunotherapy for CD33-positive pediatric acute myeloid leukemia
by: Lena Golick, et al.
Published: (2023-11-01)

The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia
by: Ana Paula Alegretti, et al.
Published: (2011-06-01)

The expression of the CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia
by: Eduardo Magalhães Rego
Published: (2011-06-01)

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances
by: Jile Liu, et al.
Published: (2023-05-01)

Pilot Study on Mass Spectrometry–Based Analysis of the Proteome of CD34+CD123+ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia
by: Johannes R. Schmidt, et al.
Published: (2018-02-01)

Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia
by: Ling Tang, et al.
Published: (2023-04-01)

Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
by: Nicole Bäumer, et al.
Published: (2022-12-01)

Uncommon CD markers in acute myeloid leukemia
by: Azad Abul Kalam, et al.
Published: (2018-12-01)

First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
by: Rupa Narayan, et al.
Published: (2024-03-01)

Evaluation The Role of CD33+ CD11b+ myeloid-derived Suppressor Cells in Patients With AML
by: Hala Hamad, et al.
Published: (2022-07-01)

Childhood acute lymphoblastic leukemia: Immunophenotypic profile and aberrant expression of CD13, CD33, CD117, CD11b, CD16, and CD64
by: Ihsan Mardan Al-Badran, et al.
Published: (2022-01-01)

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
by: Margaux Poussard, et al.
Published: (2021-02-01)

CD26/DPP-4 in Chronic Myeloid Leukemia
by: Anna Sicuranza, et al.
Published: (2022-02-01)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
by: Fatih M. Uckun, et al.
Published: (2021-08-01)

CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture
by: Maraike Harfmann, et al.
Published: (2024-01-01)

Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells
by: Zhang Y, et al.
Published: (2023-01-01)

PB1814: RARE PHENOTYPE WITH CD33 ABSENT IN ACUTE MYELOID LEUKEMIA MIMICKING MRD POSITIVITY: A CASE REPORT
by: L. O Marani, et al.
Published: (2022-06-01)

Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin
by: Wijnen NE, et al.
Published: (2023-04-01)

P482: NOVEL BISPECIFIC INNATE CELL ENGAGER AFM28 FOR THE TREATMENT OF CD123 POSITIVE ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
by: J.-J. Siegler, et al.
Published: (2022-06-01)